This Month On IVT Network |
Management Oversight of the Pharmaceutical Quality System: Obstacles and Opportunities |
|
… compliance to current good manufacturing practice (cGMP) regulations is, in fact, a part of normal pharmaceutical business that requires diligent management oversight. Read More |
LATEST JVT JOURNAL ARTICLES |
Biopharmaceutical Cleaning Validation: Acceptance Limits for Inactivated Product Based on Gelatin as a Reference Impurity |
|
Biopharmaceutical cleaning and sterilization processes denature and degrade the active pharmaceutical ingredient (API) into fragments that are pharmacologically inactive.
Read More |
cGMPS for Combination Products: 21 CFR Part 4—Final Rule |
|
The US Food and Drug Administration released its Code of Federal Regulations Title 21 Part 4, Current Good Manufacturing Practice Requirements for Combination Products, on January 22, 2013. Read More
|
Establishing a Complete Set of Target, Alert, and Action Limits for Microbial Counts in Purified Water |
|
Purified water (PW) is probably the only raw material essentially produced for internal use by pharmaceutical and other healthcare companies. Read More |
Electronic Versus Paper Change Management System–Advantages and Disadvantages |
|
Change is always around. This is especially true in the current globalized economic landscape wherein companies are facing changes on daily basis.
Read More |
LATEST GXP JOURNAL ARTICLES |
Integration of Risk Management Principles into the Quality System: Risk-based Impact Assessment |
|
As the principles of quality risk management have become increasingly pervasive in the biopharmaceutical and medical device industries, a point of saturation has been reached with respect to the risk toolkit. Read More
|
The Risk Mitigation Continuum and GMP Compliance |
|
This paper presents the case that good manufacturing practice (GMP) compliance is basically the continuous mitigation of risk to the consistent quality of the drug product throughout the manufacturing lifecycle. Read More |
Foreign Companies Beware–FDA is on a Regulatory "Warpath" |
|
Over the past year or so, you can see that US Food and Drug Administration has been taking a very "proactive" inspectional approach. Read More |
|
|